These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

206 related items for PubMed ID: 11736909

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Photoallergic dermatitis from 8-methoxypsoralen.
    Plewig G, Hofmann C, Braun-Falco O.
    Arch Dermatol Res; 1978 Apr 07; 261(2):201-11. PubMed ID: 148873
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Hepatitis from 5-methoxypsoralen occurring in a patient with previous flucloxacillin hepatitis.
    Stephens RB, Cooper A.
    Australas J Dermatol; 1999 Nov 07; 40(4):217-9. PubMed ID: 10570561
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Problems posed by the therapeutic use of photosensitizers in dermatology].
    Beani JC, Amblard P, Reymond JL.
    Biochimie; 1986 Jun 07; 68(6):905-12. PubMed ID: 2944547
    [Abstract] [Full Text] [Related]

  • 10. An unusual cause of burn injury: unsupervised use of drugs that contain psoralens.
    Türegün M, Oztürk S, Selmanpakoğlu N.
    J Burn Care Rehabil; 1999 Jun 07; 20(1 Pt 1):50-2. PubMed ID: 9934637
    [Abstract] [Full Text] [Related]

  • 11. Flu-like syndrome, bronchoconstriction and fever caused by 5-methoxypsoralen: the first case report and literature review.
    Mantovani L, Minghetti S, Maranini C, Furicchia G, Borghi A, Virgili A.
    Dermatology; 2011 Jun 07; 223(3):213-5. PubMed ID: 21576926
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. 5-Methoxypsoralen. A review of its effects in psoriasis and vitiligo.
    McNeely W, Goa KL.
    Drugs; 1998 Oct 07; 56(4):667-90. PubMed ID: 9806110
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A new micronized 5-methoxypsoralen preparation. Higher bioavailability and lower UVA dose requirement.
    Treffel P, Makki S, Humbert P, Khaldoun H, Agache P.
    Acta Derm Venereol; 1992 Oct 07; 72(1):65-7. PubMed ID: 1350152
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Time course for development of psoralen plus ultraviolet A erythema following oral administration of 5-methoxypsoralen.
    Berroeta L, Attili S, Wong A, Man I, Dawe RS, Ferguson J, Ibbotson SH.
    Br J Dermatol; 2009 Mar 07; 160(3):717-9. PubMed ID: 19183168
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.